The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-09 and is reviewed periodically as new material appears.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Identity and purity are established by instrumental methods rather than by appearance. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and yields a purity value, usually expressed as the share of total peak area. Mass spectrometry checks that the observed mass agrees with the mass calculated from the published sequence, while peptide mapping or amino acid analysis adds structural evidence. Water content, counter-ion identity and residual solvents are sometimes reported as well. A certificate of analysis should name the method behind each figure, because results are method-dependent.
Laboratory handling follows the conventions used for other synthetic peptides. Lyophilized material is weighed and dissolved in an aqueous diluent, typically sterile water or bacteriostatic water, using gentle swirling rather than vigorous shaking, because foaming stresses the chain. Solutions are prepared under clean conditions and, where sterility matters, passed through a suitable filter. Working portions are kept small so that stock material is not repeatedly warmed and cooled, a practice that limits both aggregation and gradual loss of activity.
Stability depends strongly on physical state. Dry powder is comparatively robust when held at -20 °C or below, desiccated and shielded from light; under those conditions degradation is slow and measured over years. Once dissolved, the peptide becomes far more vulnerable: backbone hydrolysis, oxidation of susceptible residues and aggregation all proceed faster in solution, and the rates climb with temperature and with pH far from neutral. Refrigerated storage at 2–8 °C extends usable life for short periods, and repeated freeze–thaw cycles are best avoided.
| Property | Value | Notes |
|---|---|---|
| Compound class | Synthetic triple-agonist peptide | Single linear chain carrying three receptor activities |
| Reported molecular weight | Approximately 4731 Da | Calculated from the published sequence; sources vary slightly |
| Appearance | White to off-white lyophilized powder | Typical of purified research-grade peptides |
| Solubility | Freely soluble in water; poorly soluble in nonpolar solvents | Dissolves in aqueous buffer near neutral pH |
| Storage of dry powder | -20 °C or below, desiccated, protected from light | Avoid repeated temperature cycling |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
ALK-positive ALCL is diagnosed by histological and immunological examinations of involved tissues, typically lymph nodes. These tissues have lymphoma-like infiltrates that have variable numbers of ALCL "hallmark" cells, i.e. cells with kidney- or horseshoe-shaped nuclei that strongly express CD30 as detected by immunohistochemistry and an ALK fusion protein as detected by fluorescence in situ hybridization. These cells are scattered throughout the infiltrates. WHO classifies these infiltrates into 5 patterns: a common pattern consisting of large variably shaped cells with large nuclei that typically contain multiple nucleoli (60–70% of cases); a small-cell pattern consisting of small to medium-sized neoplastic cells with clear cytoplasm and "hallmark" cells that are concentrated around small blood vessels (5–10% of cases); a lymphohistiocytic pattern consisting of small neoplastic cells along with abundant histiocytes (10% of cases); a Hodgkin's-like pattern in which the architecture resembles the nodular sclerosis pattern of Hodgkin lymphoma (3% of cases); and a composite pattern consisting of two or more of the just described patterns (15% of cases). Detection of circulating autoantibody against ALK supports the diagnosis. Individuals with low levels of these autoantibodies are at an increase risk of relapsing after treatment.
In 2020, PTC acquired Censa Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of CNSA-001 (sepiapterin), a clinical-stage investigational therapy for orphan metabolic diseases, including phenylketonuria (PKU) and other diseases associated with defects in the tetrahydrobiopterin (BH4) biochemical pathways diagnosed at birth. In 2020, PTC announced the FDA approval of Evrysdi (risdiplam) for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older. In 2024, Novartis has committed $1 billion upfront in a licensing deal with PTC Therapeutics for an experimental treatment for Huntington’s disease, with the potential for an additional $1.9 billion tied to achieving specific development, regulatory, and commercial milestones. PTC Therapeutics’ therapy, known as PTC518, is an oral medication designed to reduce the production of the mutant protein linked to the genetic mutation responsible for the disease. This mutant protein is believed to contribute to neuronal death, driving disease progression. In June, interim data from a Phase 2 trial indicated that PTC518 successfully lowered levels of the mutant protein in both blood and cerebrospinal fluid.
== Carbon-11 == Carbon-11 or 11C is a radioactive isotope of carbon that decays to boron-11 with a half-life to 20.34 minutes. This decay mainly occurs due to positron emission, with around 0.19–0.23% of decays instead occurring by electron capture.
Lactose is often used as the primary filler (main ingredient) in most prescription and non-prescription solid pill form medications, though product labeling seldom mentions the presence of 'lactose' or 'milk', and neither do product monograms provided to pharmacists, and most pharmacists are unaware of the very wide scale yet common use of lactose in such medications until they contact the supplier or manufacturer for verification.
"What we know about the US-Israeli attack on Iran and Tehran's retaliation". CNN. 28 February 2026. Retrieved 28 February 2026. U.S. and Israeli Strikes on Iran, C-SPAN Tracking of traffic in the Strait of Hormuz
Sources: en.wikipedia.org
==== Other medications ==== Melatonin has shown potential therapeutic value in managing fibromyalgia symptoms, including improvements in pain, sleep, anxiety levels, and quality of life. Melatonin is considered to be generally safe, hence it may be a promising supplementary treatment for fibromyalgia. Central nervous system depressants include drug categories such as sedatives, tranquilizers, and hypnotics. A 2021 meta-analysis concluded that such drugs can improve the quality of life for fibromyalgia patients in the medium term. Very low-quality evidence suggests quetiapine may be effective in fibromyalgia. Capsaicin has been suggested as a topical pain reliever. Preliminary results suggest that it may improve sleep quality and fatigue, but there are not enough studies to support this claim. Cannabinoids may have some benefits for people with fibromyalgia. However, as of 2022, the data on the topic was still limited. Cannabinoids may also have adverse effects and may negatively interact with common rheumatological drugs. No high-quality evidence exists that suggests synthetic THC (nabilone) helps with fibromyalgia. Sodium oxybate increases growth hormone production levels through increased slow-wave sleep patterns. However, this medication was not approved by the FDA for the indication for use in people with fibromyalgia due to the concern for abuse. Nonsteroidal anti-inflammatory drugs are not recommended for use as first-line therapy, and are not considered as useful in the management of fibromyalgia.
== Function == The enzyme catalyses a chemical reaction that produces a specific isomer of cyclic guanosine monophosphate–adenosine monophosphate (cGAMP) from the components guanosine triphosphate (GTP) and adenosine triphosphate (ATP), with two units of pyrophosphate (PPi) as a byproduct:
The Parliament of Barbados is the legislative branch of the government of Barbados. It is a bicameral body, composed of an appointed Senate and an elected House of Assembly. The Senate (upper house), the direct successor of a pre-Independence body known as the "Legislative Council"—comprises 21 senators appointed by the president. The President appoints 12 Senators on the advice of the Prime Minister and two on the advice of the Leader of the Opposition. The remaining seven Senators are nominated by the President at their discretion (that is, the President is not bound by other political leaders' advice in these appointments) to represent various religious, social, economic, or other interests in Barbados. In the absence of an opposition leader in parliament (i.e. in the case of a landslide victory where one party takes all 30 seats in the House of Assembly, as occurred in 2018 and 2022) the president will then appoint the remaining two senators in the opposition's stead allowing for 9 independents instead. The House of Assembly (lower house) is made up of 30 members of Parliament, elected to five-year terms on a first-past-the-post basis in single-seat constituencies.
=== Recovery and outcomes === Blepharoplasty is typically performed as an outpatient procedure and may take one to three hours depending on the extent of surgery. Postoperative swelling and bruising are common and generally resolve over several weeks. Supportive measures such as cold compresses and head elevation are often recommended during the early recovery period. Incisions are typically closed with fine sutures, which may be removed within several days in the case of external approaches or may be absorbable depending on the technique used. Suture management and wound care play a role in minimizing scarring and supporting proper healing. Results vary based on patient anatomy and surgical technique, but generally include improvement in eyelid contour, reduction of excess tissue, and a more defined eyelid–cheek junction.
Sources: en.wikipedia.org
15 November In Washington, D.C., more than 500,000 protesters staged "the largest peace march on Washington in American history" for the second "Moratorium to End the War in Vietnam". The event, which was also held on a smaller scale in other American cities, included a symbolic "March Against Death".
==== Fractures ==== Fractures can be classified as either open or closed, depending on whether the integrity of the overlying skin has been disrupted or preserved, respectively. Several classification systems have been developed to further characterize soft tissue injuries in the setting of an underlying fracture:
The establishment is a modern, structured research institute composed of six laboratories dedicated to Virology, Parasitology, Bacteriology, Medical Entomology, Clinical Biology and Pathology, including a Research Center for animals and a data center. Each laboratory is made up of a dedicated director and staff, including students and international collaborators. Each laboratory has the basic equipment and the space necessary for optimal research. It is available to faculty, students, post-docs and staff from the periphery of the INRB. Due to the structure of the INRB, if sharing and access to individual laboratory equipment is required, access is granted at the request and approval of the directors of these laboratories. The INRB common area includes some major equipment. All collaborators and researchers have, upon request, access to several -80 freezers, liquid nitrogen tanks, centrifuges, water baths, tissue homogenizers, vortexes, incubators, agitators, and all laboratories have access to cold chain equipment such as dry shippers and portable freezers. The INRB was founded in 1984 and has been a World Health Organization collaborating centre since 2018. The INRB and the World Health Organization have worked closely together on research into the effectiveness of the ring vaccination strategy during the 2018 Kivu Ebola outbreak. The National Biomedical Research Institute (INRB) has eight dynamic departments, which participate in the institute's various missions, namely monitoring, research, and training.
[C]hildren are used in many parts of the world as an illicit drug consumers market and for purposes of illicit production, distribution and trade in narcotic drugs and psychotropic substances, which entails a danger of incalculable gravity.
=== Solution === Unmodified chitosan is generally insoluble in pure water, but dissolves in dilute acidic solutions (pH < 6). It is insoluble in most organic solvents. This is because chitosan behaves like a strong base, with its primary amine groups having a pKa of about 6.3 for the reaction R-NH+3 ⇌ R−NH2 + H+. When enough hydrogen ions are present, the amine group becomes protonated, giving it a positive charge. This allows water molecules to better "pick up" chitosan in the form of a water-soluble cationic polyelectrolyte. Chitosan readily forms soluble salts with many organic acid anions, including formate, acetate, lactate, malate, citrate, glyoxylate, pyruvate, glycolate, and ascorbate. Chitosan can also be dissolved in aqueous CO2, which is useful for minimizing excess acidity. The solubility and pKa of chitosan is affected by DD%. How the acetyl groups are distributed on the chain also matters. As a polyelectrolyte, the protonation behavior of chitosan is best described by Kachalsky's equation.
Sources: en.wikipedia.org
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.
No. As of the most recent public information it remains investigational in every jurisdiction. Material sold under this name outside trials is a research chemical, not an approved medicine. Current status should always be checked against regulator notices.
Dual agonists act on two receptors, usually GIP and GLP-1. Retatrutide adds glucagon receptor activity, which is associated with increased energy expenditure. Whether that third component adds clinically meaningful benefit over dual agonism remains an open question.
Purity is normally given as a percentage from reversed-phase HPLC, calculated as the main peak area relative to total peak area. Research-grade material is commonly specified at 95 per cent or higher, with tighter specifications available. The number is method-dependent and should be read alongside the chromatogram.